铁死亡作为蛛网膜下腔出血的治疗靶点
本文综述了蛛网膜下腔出血(SAH)中细胞内铁过载通过多条生化途径促进活性自由基生成与脂质过氧化,进而诱导铁死亡并加重血管痉挛的机制,并讨论了靶向铁死亡不同环节的治疗药物;这些药物在SAH动物模型中可改善血管痉挛、神经损伤和神经行为学结局,作者认为尚需人体研究检验其安全性与疗效。
要点
- SAH中细胞内铁过载经多条生化途径促进活性自由基生成与脂质过氧化。
- 铁死亡诱导与血管痉挛加重相关,是潜在治疗靶点。
- 靶向铁死亡不同环节的药物在SAH动物模型中可改善血管痉挛、神经损伤与神经行为学结局。
核心结论
- 铁死亡是SAH神经损伤的潜在治疗靶点;靶向铁死亡不同环节的药物在SAH动物模型中可改善血管痉挛、神经损伤与神经行为学结局。
- 作者认为尚需人体研究检验鞘内或肠外给予铁死亡抑制剂改善SAH患者结局的安全性与疗效。
- 目前有少数正在进行的临床试验在探索这一治疗概念,其结果对确定铁死亡作为SAH新型治疗靶点的价值至关重要。
研究设计与样本
- 本文为综述,回顾了SAH中细胞内铁过载介导活性自由基生成与脂质过氧化的多条生化途径及其诱导铁死亡、加重血管痉挛的作用。
- 综述还讨论了通过靶向铁死亡过程不同步骤而抑制铁死亡的治疗药物。
主要发现
- SAH中细胞内铁过载通过多条生化途径介导活性自由基生成与脂质过氧化,进而诱导铁死亡并加重血管痉挛。
- 靶向铁死亡不同步骤的抑制剂在SAH动物模型中可改善血管痉挛、神经损伤和神经行为学结局。
临床怎么用
- 目前可用的SAH治疗要么对导致神经损伤的基本病理生理机制缺乏特异性,要么仅针对血管痉挛。
- 作者认为尚需人体研究检验鞘内或肠外给予铁死亡抑制剂改善SAH患者结局的安全性与疗效。
- 作者指出目前有少数正在进行的临床试验在探索这一治疗概念,其结果对确定铁死亡作为SAH新型治疗靶点的价值至关重要。
局限性
- 铁死亡抑制剂的疗效证据来自SAH动物模型,作者认为尚需人体研究检验其安全性与疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Subarachnoid hemorrhage (SAH) is a cerebrovascular disorder with significant mortality and morbidity. Neural injury in SAH is mediated through a variety of pathophysiological processes. Currently available treatments are either nonspecific in targeting the basic pathophysiological mechanisms that result in neural damage in SAH, or merely focus on vasospasm. Ferroptosis is a type of programmed iron dependent cell death, which has received attention due to its possible role in neural injury in SAH. Herein, we review how intracellular iron overload mediates the production of reactive free radicals and lipid peroxidation through a variety of biochemical pathways in SAH. This in turn results in induction of ferroptosis, as well as exacerbation of vasospasm. We also discuss several therapeutic agents that have been shown to inhibit ferroptosis through targeting different steps of the process. Such agents have proven effective in ameliorating vasospasm, neural damage, and neurobehavioral outcomes in animal models of SAH. Human studies to test the safety and efficacy of intrathecal or parenteral administration of the inhibitors of ferroptosis in improving outcomes of SAH patients are warranted. There are currently a few ongoing clinical trials pursuing this therapeutic concept, the results of which will be critical to determine the value of ferroptosis as a novel therapeutic target in SAH.
引用
- Dabbagh Ohadi MA, Maroufi SF, Mohammadi MR, et al. Ferroptosis as a Therapeutic Target in Subarachnoid Hemorrhage. World Neurosurg. 2023. PMID: 37979679. doi:10.1016/j.wneu.2023.11.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。